InsiderTrades.com logo
The Ultimate Passive Income Play
From The Oxford Club   |   Ad
The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas. 

Find Out What It Is Right Here.
>>>

SABS Insider Trading

Insider Ownership Percentage: 31.90%
Insider Buying (Last 12 Months): $7,300.00
Insider Selling (Last 12 Months): $0.00

SAB Biotherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at SAB Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

SAB Biotherapeutics Share Price & Price History

Current Price: $0.92
Price Change: ▲ Price Increase of +0.01 (1.10%)
As of 06/2/2023 01:00 AM ET

This chart shows the closing price history over time for SABS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Ultimate Passive Income Play
From The Oxford Club   |   Ad
The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas. 

Find Out What It Is Right Here.
>>>

SAB Biotherapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2022Christine E HamiltonDirectorBuy10,000$0.73$7,300.004,993,090View SEC Filing Icon  
See Full Table
27 U.S. Cities Where Stocks Yield 26% a Year
From Investing Daily   |   Ad
What’s the highest-yielding stock you’ve ever owned?

The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.

SEC Filings (Institutional Ownership Changes) for SAB Biotherapeutics (NASDAQ:SABS)

20.94% of SAB Biotherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SABS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

SAB Biotherapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/16/2023First Manhattan CO. LLC.277,777$0.12M0.0%N/A0.551%Search for SEC Filing on Google Icon
2/16/2023Shaolin Capital Management LLC236,621$0.14M0.0%-14.0%0.469%Search for SEC Filing on Google Icon
2/15/2023Meteora Capital LLC134,524$79K0.0%-46.1%0.267%Search for SEC Filing on Google Icon
2/13/2023Geode Capital Management LLC300,529$0.18M0.0%-5.1%0.596%Search for SEC Filing on Google Icon
2/9/2023HighTower Advisors LLC75,970$44K0.0%N/A0.151%Search for SEC Filing on Google Icon
2/2/2023Silver Oak Securities Incorporated51,941$31K0.0%N/A0.121%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.701,003$0.49M0.0%-2.9%1.629%Search for SEC Filing on Google Icon
11/15/2022Citadel Advisors LLC40,162$28K0.0%N/A0.093%Search for SEC Filing on Google Icon
11/7/2022Institutional & Family Asset Management LLC149,774$0.11M0.0%+91.7%0.348%Search for SEC Filing on Google Icon
10/20/2022First PREMIER Bank807,535$0.57M0.2%+23.8%1.877%Search for SEC Filing on Google Icon
8/15/2022State Street Corp81,241$0.12M0.0%+91.9%0.189%Search for SEC Filing on Google Icon
8/15/2022Millennium Management LLC64,220$93K0.0%N/A0.149%Search for SEC Filing on Google Icon
8/15/2022LGL Partners LLC23,000$33K0.0%N/A0.054%Search for SEC Filing on Google Icon
8/3/2022AE Wealth Management LLC18,700$27K0.0%N/A0.044%Search for SEC Filing on Google Icon
7/26/2022First PREMIER Bank652,440$0.95M0.3%N/A1.519%Search for SEC Filing on Google Icon
5/16/2022State Street Corp42,341$0.16M0.0%+244.2%0.099%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.721,151$2.71M0.0%+5.6%1.679%Search for SEC Filing on Google Icon
5/9/2022Qube Research & Technologies Ltd24,179$91K0.0%+43.8%0.056%Search for SEC Filing on Google Icon
2/14/2022Radcliffe Capital Management L.P.546,658$5.52M0.1%N/A1.257%Search for SEC Filing on Google Icon
2/14/2022ETF Managers Group LLC13,202$0.11M0.0%N/A0.030%Search for SEC Filing on Google Icon
2/14/2022Institutional & Family Asset Management LLC78,115$0.61M0.1%N/A0.180%Search for SEC Filing on Google Icon
2/10/2022Qube Research & Technologies Ltd16,817$0.13M0.0%N/A0.039%Search for SEC Filing on Google Icon
2/9/2022Wolverine Asset Management LLC6,602$51K0.0%N/A0.015%Search for SEC Filing on Google Icon
2/9/2022Alps Advisors Inc.50,306$0.39M0.0%N/A0.116%Search for SEC Filing on Google Icon
2/3/2022Spectrum Management Group LLC5,030$39K0.0%N/A0.012%Search for SEC Filing on Google Icon
2/1/2022Qube Research & Technologies Ltd16,817$0.13M0.0%N/A0.039%Search for SEC Filing on Google Icon
1/19/2022First PREMIER Bank832,555$6.50M1.7%N/A1.915%Search for SEC Filing on Google Icon
1/18/2022Nadler Financial Group Inc.11,000$86K0.0%N/A0.025%Search for SEC Filing on Google Icon
11/17/2021Tudor Investment Corp Et Al60,000$0.61M0.0%N/A0.406%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
SAB Biotherapeutics logo
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Read More on SAB Biotherapeutics

Today's Range

Now: $0.92
Low: $0.88
High: $0.92

50 Day Range

MA: $0.76
Low: $0.38
High: $1.09

52 Week Range

Now: $0.92
Low: $0.37
High: $2.19

Volume

34,772 shs

Average Volume

139,557 shs

Market Capitalization

$46.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41

Who are the company insiders with the largest holdings of SAB Biotherapeutics?

SAB Biotherapeutics' top insider shareholders include:
  1. Christine E Hamilton (Director)
Learn More about top insider investors at SAB Biotherapeutics.

Who are the major institutional investors of SAB Biotherapeutics?

SAB Biotherapeutics' top institutional investors include:
  1. First Manhattan CO. LLC. — 0.55%
Learn More about top institutional investors of SAB Biotherapeutics stock.

Which institutional investors are buying SAB Biotherapeutics stock?

In the last quarter, SABS stock was bought by institutional investors including:
  1. First Manhattan CO. LLC.
27 U.S. Cities Where Stocks Yield 26% a Year
From Investing Daily   |   Ad
What’s the highest-yielding stock you’ve ever owned?

The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.